midry eye products

Managing dry eye effectively starts with understanding the underlying cause. Idra by SBM Sistemi helps practitioners move from subjective symptoms to objective, measurable evaluation of the ocular surface.

With detailed analysis of tear film, lipid layer, meibomian glands, tear volume, and blinking, Idra provides clear data that can also help patients understand their condition and engage with their treatment. This allows practitioners to identify the right treatment pathway without unnecessary delays.

Complementing diagnosis, Activa by SBM Sistemi offers an in-practice treatment solution for meibomian gland dysfunction, helping practices connect objective diagnosis with targeted treatment and ongoing patient management.

Contact: BOC Instruments (AUS) 1800 804 331 or sales@bocinstruments.com.au

TearStim uses patented intense regulated pulsed light (IRPL) technology for the management of evaporative dry eye associated with meibomian gland dysfunction (MGD).

Precisely controlled, sequenced light pulses are designed to stimulate meibomian gland function, improve glandular secretion, and support tear film stability. Clinical research into IRPL has reported improvements in non-invasive tear break-up time, lipid layer thickness, and tear osmolarity, alongside improvements in patient reported symptoms.

With a short treatment protocol designed for clinical practice, TearStim provides eye care professionals with a technology-based option for expanding dry eye management beyond symptomatic relief.

Contact: Eyetek (AUS) 1300 618 336 or excellent@eyetek.com.au

Zest is an in-office treatment created by ophthalmologist Dr Peter Pham.

This simple, office-based treatment uses a specialised gel and cleaning swab to gently lift and remove biofilm through an enzymatic-like biomechanical process that does not induce further tissue injury. Clinical improvements in signs and symptoms are often felt within minutes. No additional equipment or anaesthetic eye drops are required.

Zest is based on okra polysaccharides (or complex sugars) derived from fresh okra. It also contains the following ingredients to add to chemical stability and performance: (natural ingredients and emollients) aloe vera leaf juice, hydrolysed soy protein, caffeine, citrus unshiu peel extract, and raspberry seed oil; (wetting agents) carboxymethyl cellulose and glycerin; (preservatives) ethylhexylglycerin and phenoxyethanol; (surfactants) decyl glucoside and disodium cocoamphodiacetate. It also includes the chelator sodium phytate and sodium chloride solution.

Contact: Good Optical (AUS) 03 9645 1066 or orders@goodoptical.com.au

DryEye Forte is a practitioner-dispensed oral nutritional supplement designed to complement topical and in-practice treatments as part of a multimodal approach to dry eye management.

Its formula works systemically to support tear film function and anti-inflammatory pathways, combining re-esterified fish-oil omega-3 (EPA and DHA), GLA from borage oil, antioxidant vitamin E, and vitamin D3.

DryEye Forte delivers 1,200 mg EPA and DHA daily. Randomised clinical trials and meta-analyses of omega-3 supplementation have reported improvements in dry eye symptoms and measures of tear film and ocular surface health.1-4 Vitamin D deficiency has been associated with greater dry eye symptoms and reduced tear production.5 Recommended and sold through eye care professionals.

Contact: MD EyeCare (AUS) 1300 952 001 or (NZ) 0800 443 652

Espansione’s eye-light combines intense pulsed light (IPL) with low-level light therapy (LLLT/photobiomodulation) to support the management of dry eye associated with meibomian gland dysfunction (MGD).

This combined approach is specifically featured in the Tear Film and Ocular Surface Society Dry Eye Workshop III (TFOS DEWS III) Management and Therapy report, which cites multiple studies using eye-light IPL and LLLT in patients with MGD.¹ The complementary technologies provide clinicians with a non-invasive, in-practice approach to managing tear film instability and evaporative dry eye beyond symptomatic lubrication alone. With growing clinical evidence supporting light-based therapies, eye-light provides an integrated platform for personalised, evidence-based chronic dry eye management.

Visit: ophthalmopro.com.au

Confidently diagnose and subtype dry eye disease with comprehensive insights from the Medmont Meridia Vantage. Built to streamline your clinic’s workflow, it integrates advanced corneo-scleral topography and high-definition imaging with a complete ocular surface analysis suite. Versatile scleral profilometry and intuitive software empower you to fit the specialty lenses that are essential for managing complex cases.

Featuring high-resolution photo and video alongside clear patient reports, the Medmont Meridia Vantage helps build immediate trust, foster long-term compliance, and visually demonstrate treatment progress over time.

Contact: Medmont International (AUS) 03 9259 0800

Dry eye disease (DED) is driven by multiple pathogenic mechanisms, including inflammation.¹ The Tear Film and Ocular Surface Society Dry Eye Workshop III (TFOS DEWS III) framework recommends identifying each patient’s specific disease drivers and tailoring management accordingly.² Multiple treatments, used in combination, may be required to address the underlying drivers of DED.² In patients with an inflammatory component, topical ciclosporin can be incorporated into a broader treatment strategy.²

Cequa (ciclosporin 900 microgram/mL) is an aqueous, nanomicellar, ophthalmic, ciclosporin solution indicated to increase tear production in patients with moderate to severe dry eye disease where prior use of artificial tears has been insufficient.3,4 It is available for prescribing in both Australia and New Zealand.

Contact: Sun Pharma ANZ (AUS) 1800 726 229 or (NZ) 0800 726 229

Pharmaceutical Benefits Scheme (PBS) information: Authority required. Refer to PBS schedule for full authority information. Please review Product Information before prescribing, available from ebs.tga.gov.au.

Pharmac Status: Cequa is an unfunded prescription medicine – your patients will have to pay for this medicine and any healthcare professional fees. Before prescribing Cequa, read the Data Sheet for information on dosage, contraindications, precautions, interactions, and adverse effects. The Data Sheet is available from medsafe.govt.nz.

Rohto Dry Aid is a multi-component lubricant eye drop designed to support tear film stability across aqueous-deficient and evaporative dry eye. Its Tearshield Technology combines polar and non-polar lipid-like components designed to interact with the lipid layer and support more normal tear film mechanics, particularly in meibomian gland dysfunction-driven evaporative dry eye.¹ Clinical evidence has demonstrated significant improvements in ocular discomfort,² while Rohto Dry Aid has also been studied as a comfort-enhancing adjunct to prescription dry-eye therapies.2 Available in preservative-free and multidose formulations, Rohto Dry Aid provides clinicians with a versatile option for ongoing dry eye management.

Contact: OphthalmoPro (AUS) 1300 578 288 or (NZ) 0800 578 288

Lacritec, as a systemic approach to dry eye treatment, is well placed to augment other dry eye treatments to improve outcomes. Lacritec combines the benefits of concentrated fish oil, borage oil, and flaxseed oil.

The physiological and nutrigenomic benefits of alpha-linolenic acid (ALA), which is derived from flaxseed oil, result in a systemic lowering of inflammatory cytokines and prostaglandins that have been directly associated with dry eye symptoms. Specifically, a review on the effect ALA has on interleukin 6 and prostaglandin E2 highlights the unique benefit flaxseed oil provides in the treatment for dry eye disease.1

Contact: Stiltec (AUS) 1800 622 883

Albomed Pe-Ha Guard HPMC 2.0% corneal lubricant is easy to use and highly effective in protecting the corneal epithelium during ophthalmic procedures such as cataract surgery, vitreoretinal surgery, and glaucoma surgery. Albomed Pe-Ha Guard may increase the safety of surgery by optimising the surgical view without interruptions. Other advantages include greater workflow efficiency as it frees up the scrub nurse from frequently applying balanced salt solution intraoperatively. Studies have shown improved patient comfort postoperatively as it significantly reduces dry eye issues after surgery.1,2 It may also help to ensure optimum outcomes following surgery involving extended depth of field and multifocal intraocular lenses.

Contact: SurgiVision (AUS) 1300 995 132 or sales@surgivision.com.au

As the world’s leading minimally invasive glaucoma surgery (MIGS) platform,1 iStent technologies have been shown to reduce topical medication burden by 69%,2 with this reduction sustained for up to seven years.3 By reducing reliance on topical eye drops, iStent technologies have also been associated with a 72% reduction in the proportion of patients experiencing severe ocular surface disease symptoms.4

Treating a patient’s glaucoma with iStent infinite can have the added benefit of assisting the cornea. Whether implanted in conjunction with cataract surgery or as a standalone procedure, iStent technologies have demonstrated significant and durable improvements in quality of life.5

Visit: glaukos.net.au

ScoutPro by Trukera Medical delivers high-quality, precise tear osmolarity testing, putting laboratory-level accuracy in the palm of your hand. This portable, all-in-one device, featuring integrated VeriLyte technology, is an intelligent solution for enhanced clinical efficiency and patient care in managing chronic dry eye disease. It provides immediate, on-device results, enabling improved tear film assessment and informed surgical decision-making. By accurately assessing tear film stability and reducing biometry variability, ScoutPro helps refractive and cataract surgeons achieve more consistent surgical outcomes. IQ Medical is committed to delivering this innovation and fostering strong collaborative partnerships to help transform patients’ lives.

Contact: IQ Medical (AUS) 08 8357 8022 or visit iqmedical.com.au

NovaTears is a preservative-free eye drop that uses patented EyeSol technology to target evaporative dry eye – the primary driver of dry eye disease.

Formulated without water, preservatives, phosphates, or surfactants, NovaTears forms a protective barrier over the tear film’s lipid layer, reducing evaporation and supporting the aqueous layer to benefit patients with all forms of dry eye.

It is clinically proven to significantly reduce symptoms within five minutes,1 improve signs and symptoms within two weeks,1-3 and sustain improvement over 52 weeks,4 with a use-by period of six months after opening.

Contact: AFT Pharmaceuticals (AUS) 1800 238 742 or (NZ) 0800 423 823

The Tera Dry Eye Imager is a full Placido-based corneal topographer designed for the comprehensive assessment of corneal properties and pupil metrics. It also provides advanced tools for the assessment, grading, and monitoring of dry eye disease, alongside detailed measurements of anterior corneal topography, simulated aberrations, and pupillography to support contact lens fitting and differential diagnosis. Aligned with Tear Film and Ocular Surface Society Dry Eye Workshop III (TFOS DEWS III) recommendations, its non-invasive assessments – including tear meniscus height, non-invasive tear break-up time, blink analysis, lipid layer assessment, and meibography – support personalised care pathways and more targeted treatment decisions.

Visit: topconhealthcare.com.au/products/tera